Endocrine Abstracts

Introduction: Alemtuzumab is a humanized anti-CD52 monoclonal antibody approved for the treatment of relapsing−remitting multiple sclerosis (RRMS). Through an immune reconstitution mechanism, it leads to thyroid autoimmunity in 35% of cases, with Graves’ disease (GD) being the most common presentation. Alemtuzumab-induced GD exhibits distinctive clinical and immunological features, with rarely reported cases of fluctuating thyroid status with documented both blockin...

Background: In 15% of prolactinomas there is dopamine agonist(DA) resistance. The clinical characteristics, the best diagnostic and therapeutic management of these cases have not been established so far.Aim: To characterize patients taking a high dose cabergoline(≥ 3mg/week) and then describe clinical, biochemical and imaging features of cabergoline-resistant cases.Methods: Retrospective study with 5 centers representing the ...

IntroductionThe close relationship between cancer and thrombotic phenomena has been widely recognized and paraneoplastic organ infarctions may occur. Reports of papillary thyroid cancer associated to paraneoplastic phenomena are particularly scarce.Case reportA 39-year-old man with no prior relevant medical history was evaluated for acute onset of fever, malaise and mild pain referred to his left hypochondriu...